Advertisement
Advertisement
U.S. Markets close in 4 hrs 55 mins
Advertisement
Advertisement
Advertisement
Advertisement

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
35.16-1.57 (-4.27%)
As of 04:00PM EST. Market open.
Advertisement

Xencor, Inc.

111 West Lemon Avenue
Monrovia, CA 91016
United States
626 305 5900
http://www.xencor.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees202

Key Executives

NameTitlePayExercisedYear Born
Dr. Bassil I. Dahiyat Ph.D.Co-Founder, CEO, Pres & Director971.93kN/A1970
Mr. John J. KuchSr. VP & CFO584.93k173.8k1959
Dr. John R. DesjarlaisSr. VP of Research & Chief Scientific Officer637.93kN/A1964
Ms. Celia E. Eckert J.D.VP, Gen. Counsel & Corp. Sec.572.86kN/A1972
Dr. Allen S. Yang M.D., Ph.D.Sr. VP & Chief Medical Officer678.93kN/A1968
Mr. Charles LilesAssociate Director and Head of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Jennifer SandozVP of HRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., Janssen Biotech, Inc.; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Corporate Governance

Xencor, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement